| Hydroxyzine | hsa00030 | Pentose phosphate pathway | 3.06E-04 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | |
| Hydroxyzine | hsa00190 | Oxidative phosphorylation | 2.29E-02 | 2 | Q16718, O14521 | NDUFA5, SDHD | More | |
| Hydroxyzine | hsa00310 | Lysine degradation | 2.59E-02 | 2 | Q96KQ7, P51648 | EHMT2, ALDH3A2 | More | |
| Hydroxyzine | hsa00512 | Mucin type O-glycan biosynthesis | 4.86E-02 | 2 | O95395, Q9NY28 | GCNT3, GALNT8 | More | |
| Hydroxyzine | hsa00630 | Glyoxylate and dicarboxylate metabolism | 9.21E-03 | 2 | P40925, P15104 | MDH1, GLUL | More | |
| Hydroxyzine | hsa00760 | Nicotinate and nicotinamide metabolism | 3.52E-02 | 1 | P21589 | NT5E | More | |
| Hydroxyzine | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | |
| Hydroxyzine | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | |
| Hydroxyzine | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | |
| Hydroxyzine | hsa01521 | EGFR tyrosine kinase inhibitor resistance | 3.18E-04 | 2 | P04049, P08069 | RAF1, IGF1R | More | |
| Hydroxyzine | hsa01522 | Endocrine resistance | 4.47E-04 | 2 | P04049, P08069 | RAF1, IGF1R | More | |
| Hydroxyzine | hsa02010 | ABC transporters | 2.29E-02 | 2 | P45844, P08183 | ABCG1, ABCB1 | More | |
| Hydroxyzine | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | |
| Hydroxyzine | hsa03040 | Spliceosome | 1.08E-02 | 7 | Q14562, O43143, O60508, Q07955, Q01130, Q13243, P11142 | DHX8, DHX15, CDC40, SFRS1, SFRS2, SFRS5, HSPA8 | More | |
| Hydroxyzine | hsa04010 | MAPK signaling pathway | 1.69E-03 | 2 | P04049, P08069 | RAF1, IGF1R | More | |
| Hydroxyzine | hsa04012 | ErbB signaling pathway | 1.82E-02 | 1 | P04049 | RAF1 | More | |
| Hydroxyzine | hsa04014 | Ras signaling pathway | 1.26E-03 | 9 | P04049, Q9NRA1, P08069, Q13009, P0DP23, P62873, P63218, P50151, P19174 | RAF1, PDGFC, IGF1R, TIAM1, CALM1, GNB1, GNG5, GNG10, PLCG1 | More | |
| Hydroxyzine | hsa04015 | Rap1 signaling pathway | 8.67E-04 | 2 | P04049, P08069 | RAF1, IGF1R | More | |
| Hydroxyzine | hsa04022 | cGMP-PKG signaling pathway | 3.15E-02 | 1 | P04049 | RAF1 | More | |
| Hydroxyzine | hsa04024 | cAMP signaling pathway | 2.49E-02 | 1 | P04049 | RAF1 | More | |
| Hydroxyzine | hsa04060 | Cytokine-cytokine receptor interaction | 4.71E-02 | 2 | P78552, O75509 | IL13RA1, TNFRSF21 | More | |
| Hydroxyzine | hsa04062 | Chemokine signaling pathway | 5.80E-04 | 10 | P07948, P19174, P62873, P63218, P50151, Q13009, P14598, P42224, P04049, P25963 | LYN, PLCG1, GNB1, GNG5, GNG10, TIAM1, NCF1, STAT1, RAF1, NFKBIA | More | |
| Hydroxyzine | hsa04066 | HIF-1 signaling pathway | 2.16E-02 | 1 | P08069 | IGF1R | More | |
| Hydroxyzine | hsa04068 | FoxO signaling pathway | 3.80E-04 | 2 | P04049, P08069 | RAF1, IGF1R | More | |
| Hydroxyzine | hsa04070 | Phosphatidylinositol signaling system | 2.93E-02 | 4 | P19174, P0DP23, P23743, P27987 | PLCG1, CALM1, DGKA, ITPKB | More | |
| Hydroxyzine | hsa04071 | Sphingolipid signaling pathway | 3.35E-03 | 5 | P04049, P21453, Q9H228, P01375, Q13362 | RAF1, S1PR1, EDG8, TNF, PPP2R5C | More | |
| Hydroxyzine | hsa04072 | Phospholipase D signaling pathway | 7.52E-04 | 3 | P04049, Q92529, Q14344 | RAF1, SHC3, GNA13 | More | |
| Hydroxyzine | hsa04080 | Neuroactive ligand-receptor interaction | 1.97E-02 | 5 | P28472, P21453, Q9H228, P21730, P07550 | GABRB3, S1PR1, EDG8, C5AR1, ADRB2 | More | |
| Hydroxyzine | hsa04114 | Oocyte meiosis | 2.99E-02 | 1 | P08069 | IGF1R | More | |
| Hydroxyzine | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | |
| Hydroxyzine | hsa04140 | Autophagy - animal | 7.72E-04 | 2 | P08069, P04049 | IGF1R, RAF1 | More | |
| Hydroxyzine | hsa04141 | Protein processing in endoplasmic reticulum | 8.60E-03 | 6 | P30101, P60604, P11142, P08238, Q9H173, Q9UNL2 | PDIA3, UBE2G2, HSPA8, HSP90AB1, SIL1, SSR3 | More | |
| Hydroxyzine | hsa04145 | Phagosome | 6.51E-03 | 6 | P11215, P14598, Q71U36, Q13509, P68371, Q13488 | ITGAM, NCF1, TUBA1A, TUBB3, TUBB2C, TCIRG1 | More | |
| Hydroxyzine | hsa04150 | mTOR signaling pathway | 5.20E-04 | 2 | P08069, P04049 | IGF1R, RAF1 | More | |
| Hydroxyzine | hsa04152 | AMPK signaling pathway | 1.99E-02 | 1 | P08069 | IGF1R | More | |
| Hydroxyzine | hsa04210 | Apoptosis | 2.16E-02 | 1 | P04049 | RAF1 | More | |
| Hydroxyzine | hsa04211 | Longevity regulating pathway | 2.16E-02 | 1 | P08069 | IGF1R | More | |
| Hydroxyzine | hsa04213 | Longevity regulating pathway - multiple species | 2.83E-03 | 3 | P08069, Q9Y4H2, Q13547 | IGF1R, IRS2, HDAC1 | More | |
| Hydroxyzine | hsa04217 | Necroptosis | 2.34E-02 | 4 | P01375, P48023, Q14765, Q99878 | TNF, FASLG, STAT4, H2AC14 | More | |
| Hydroxyzine | hsa04218 | Cellular senescence | 2.49E-02 | 1 | P04049 | RAF1 | More | |
| Hydroxyzine | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.95E-02 | 4 | P07550, P22694, P18848, Q13362 | ADRB2, PRKACB, ATF4, PPP2R5C | More | |
| Hydroxyzine | hsa04270 | Vascular smooth muscle contraction | 2.32E-02 | 1 | P04049 | RAF1 | More | |
| Hydroxyzine | hsa04360 | Axon guidance | 2.49E-02 | 1 | P04049 | RAF1 | More | |
| Hydroxyzine | hsa04370 | VEGF signaling pathway | 8.29E-03 | 1 | P04049 | RAF1 | More | |
| Hydroxyzine | hsa04371 | Apelin signaling pathway | 3.46E-04 | 8 | P62873, P63218, P50151, P04049, Q13370, Q14344, P84022, P0DP23 | GNB1, GNG5, GNG10, RAF1, PDE3B, GNA13, SMAD3, CALM1 | More | |
| Hydroxyzine | hsa04510 | Focal adhesion | 1.18E-03 | 2 | P04049, P08069 | RAF1, IGF1R | More | |
| Hydroxyzine | hsa04520 | Adherens junction | 8.29E-03 | 1 | P08069 | IGF1R | More | |
| Hydroxyzine | hsa04540 | Gap junction | 2.22E-03 | 5 | Q13509, P68371, Q71U36, P04049, Q9NRA1 | TUBB3, TUBB2C, TUBA1A, RAF1, PDGFC | More | |
| Hydroxyzine | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 3.80E-04 | 2 | P04049, P08069 | RAF1, IGF1R | More | |
| Hydroxyzine | hsa04612 | Antigen processing and presentation | 1.07E-03 | 6 | Q14953, P26715, P26717, Q13241, P01732, P01375 | KIR2DS5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | |
| Hydroxyzine | hsa04613 | Neutrophil extracellular trap formation | 2.71E-05 | 11 | P04049, P11215, Q13547, P04908, Q93077, P58876, Q16778, O60814, P68431, O43315, Q16539 | RAF1, ITGAM, HDAC1, H2AC4; H2AC8, HIST1H2AC, H2BC5, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, AQP9, MAPK14 | More | |
| Hydroxyzine | hsa04623 | Cytosolic DNA-sensing pathway | 2.59E-02 | 2 | P01568, P25963 | IFNA21, NFKBIA | More | |
| Hydroxyzine | hsa04625 | C-type lectin receptor signaling pathway | 1.49E-02 | 1 | P04049 | RAF1 | More | |
| Hydroxyzine | hsa04630 | JAK-STAT signaling pathway | 1.49E-02 | 1 | P04049 | RAF1 | More | |
| Hydroxyzine | hsa04650 | Natural killer cell mediated cytotoxicity | 2.93E-05 | 8 | P01375, P20963, P04049, Q13241, P26718, P26717, Q14953, P26715 | TNF, CD247, RAF1, KLRD1, KLRK1, KLRC2, KIR2DS5, KLRC1 | More | |
| Hydroxyzine | hsa04657 | IL-17 signaling pathway | 2.41E-02 | 4 | P19875, P14780, P80188, P01375 | CXCL2, MMP9, LCN2, TNF | More | |
| Hydroxyzine | hsa04659 | Th17 cell differentiation | 1.11E-02 | 6 | P25963, P19174, P42224, P14784, P84022, P08238 | NFKBIA, PLCG1, STAT1, IL2RB, SMAD3, HSP90AB1 | More | |
| Hydroxyzine | hsa04660 | T cell receptor signaling pathway | 1.66E-02 | 1 | P04049 | RAF1 | More | |
| Hydroxyzine | hsa04662 | B cell receptor signaling pathway | 9.95E-03 | 1 | P04049 | RAF1 | More | |
| Hydroxyzine | hsa04664 | Fc epsilon RI signaling pathway | 1.24E-03 | 5 | P04141, P07948, P19174, P04049, P09917 | CSF2, LYN, PLCG1, RAF1, ALOX5 | More | |
| Hydroxyzine | hsa04666 | Fc gamma R-mediated phagocytosis | 2.32E-02 | 1 | P04049 | RAF1 | More | |
| Hydroxyzine | hsa04668 | TNF signaling pathway | 3.55E-02 | 4 | P01375, P18848, P19875, P14780 | TNF, ATF4, CXCL2, MMP9 | More | |
| Hydroxyzine | hsa04713 | Circadian entrainment | 2.18E-02 | 4 | P0DP23, P62873, P63218, P50151 | CALM1, GNB1, GNG5, GNG10 | More | |
| Hydroxyzine | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | |
| Hydroxyzine | hsa04720 | Long-term potentiation | 1.66E-02 | 1 | P04049 | RAF1 | More | |
| Hydroxyzine | hsa04722 | Neurotrophin signaling pathway | 7.10E-03 | 4 | P04049, P49841, O43524, P48023 | RAF1, GSK3B, FOXO3, FASLG | More | |
| Hydroxyzine | hsa04724 | Glutamatergic synapse | 1.57E-02 | 4 | P62873, P63218, P50151, P15104 | GNB1, GNG5, GNG10, GLUL | More | |
| Hydroxyzine | hsa04726 | Serotonergic synapse | 5.74E-03 | 5 | P62873, P63218, P50151, P09917, P04049 | GNB1, GNG5, GNG10, ALOX5, RAF1 | More | |
| Hydroxyzine | hsa04727 | GABAergic synapse | 4.18E-03 | 4 | P62873, P63218, P50151, P15104 | GNB1, GNG5, GNG10, GLUL | More | |
| Hydroxyzine | hsa04730 | Long-term depression | 4.15E-04 | 4 | Q14344, P08069, P04049, P07948 | GNA13, IGF1R, RAF1, LYN | More | |
| Hydroxyzine | hsa04744 | Phototransduction | 9.21E-03 | 2 | P62873, P0DP23 | GNB1, CALM1 | More | |
| Hydroxyzine | hsa04810 | Regulation of actin cytoskeleton | 3.81E-02 | 1 | P04049 | RAF1 | More | |
| Hydroxyzine | hsa04910 | Insulin signaling pathway | 1.49E-02 | 1 | P04049 | RAF1 | More | |
| Hydroxyzine | hsa04912 | GnRH signaling pathway | 1.82E-02 | 1 | P04049 | RAF1 | More | |
| Hydroxyzine | hsa04913 | Ovarian steroidogenesis | 7.72E-03 | 3 | P42330, P22694, P08069 | AKR1C3, PRKACB, IGF1R | More | |
| Hydroxyzine | hsa04914 | Progesterone-mediated oocyte maturation | 4.47E-04 | 2 | P08069, P04049 | IGF1R, RAF1 | More | |
| Hydroxyzine | hsa04915 | Estrogen signaling pathway | 2.99E-02 | 1 | P04049 | RAF1 | More | |
| Hydroxyzine | hsa04916 | Melanogenesis | 1.33E-02 | 1 | P04049 | RAF1 | More | |
| Hydroxyzine | hsa04917 | Prolactin signaling pathway | 6.63E-03 | 1 | P04049 | RAF1 | More | |
| Hydroxyzine | hsa04919 | Thyroid hormone signaling pathway | 1.82E-02 | 1 | P04049 | RAF1 | More | |
| Hydroxyzine | hsa04921 | Oxytocin signaling pathway | 2.32E-02 | 1 | P04049 | RAF1 | More | |
| Hydroxyzine | hsa04924 | Renin secretion | 4.04E-02 | 2 | P22694, P07550 | PRKACB, ADRB2 | More | |
| Hydroxyzine | hsa04926 | Relaxin signaling pathway | 6.24E-03 | 5 | P18848, P22694, P14780, P04049, P30679 | ATF4, PRKACB, MMP9, RAF1, GNA15 | More | |
| Hydroxyzine | hsa04927 | Cortisol synthesis and secretion | 2.54E-02 | 2 | P18848, P22694 | ATF4, PRKACB | More | |
| Hydroxyzine | hsa04928 | Parathyroid hormone synthesis, secretion and action | 1.99E-02 | 1 | P04049 | RAF1 | More | |
| Hydroxyzine | hsa04929 | GnRH secretion | 4.98E-03 | 1 | P04049 | RAF1 | More | |
| Hydroxyzine | hsa04932 | Non-alcoholic fatty liver disease | 2.44E-03 | 5 | P01375, P49841, P48023, Q16718, O14521 | TNF, GSK3B, FASLG, NDUFA5, SDHD | More | |
| Hydroxyzine | hsa04935 | Growth hormone synthesis, secretion and action | 2.16E-02 | 1 | P04049 | RAF1 | More | |
| Hydroxyzine | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
| Hydroxyzine | hsa04960 | Aldosterone-regulated sodium reabsorption | 4.38E-02 | 1 | P48048 | KCNJ1 | More | |
| Hydroxyzine | hsa04970 | Salivary secretion | 1.91E-02 | 3 | P07550, P22694, P49913 | ADRB2, PRKACB, CAMP | More | |
| Hydroxyzine | hsa04976 | Bile secretion | 3.32E-02 | 2 | O43315, P08183 | AQP9, ABCB1 | More | |
| Hydroxyzine | hsa05012 | Parkinson disease | 1.77E-02 | 6 | P60604, P19174, P0DP23, Q71U36, Q13509, P68371 | UBE2G2, PLCG1, CALM1, TUBA1A, TUBB3, TUBB2C | More | |
| Hydroxyzine | hsa05020 | Prion disease | 3.80E-02 | 4 | Q16718, O14521, P49841, Q16539 | NDUFA5, SDHD, GSK3B, MAPK14 | More | |
| Hydroxyzine | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.24E-02 | 6 | P49841, Q16718, O14521, Q13561, Q16539, Q08752 | GSK3B, NDUFA5, SDHD, DCTN2, MAPK14, PPID | More | |
| Hydroxyzine | hsa05031 | Amphetamine addiction | 4.32E-02 | 3 | P22694, P18848, Q13547 | PRKACB, ATF4, HDAC1 | More | |
| Hydroxyzine | hsa05032 | Morphine addiction | 2.18E-02 | 4 | P62873, P63218, P50151, Q13370 | GNB1, GNG5, GNG10, PDE3B | More | |
| Hydroxyzine | hsa05034 | Alcoholism | 1.49E-04 | 5 | Q13547, P04049, P58876, Q16778, O60814 | HDAC1, RAF1, H2BC5, HIST2H2BE, H2BC12 | More | |
| Hydroxyzine | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 1.08E-02 | 4 | P25963, Q13488, P19174, P07948 | NFKBIA, TCIRG1, PLCG1, LYN | More | |
| Hydroxyzine | hsa05130 | Pathogenic Escherichia coli infection | 3.19E-02 | 6 | Q71U36, P16333, Q13509, P68371, Q14344, P25963 | TUBA1A, NCK1, TUBB3, TUBB2C, GNA13, NFKBIA | More | |
| Hydroxyzine | hsa05132 | Salmonella infection | 1.82E-02 | 8 | P25963, P08238, P04049, O75369, Q71U36, Q13509, P68371, P49754 | NFKBIA, HSP90AB1, RAF1, FLNB, TUBA1A, TUBB3, TUBB2C, VPS41 | More | |
| Hydroxyzine | hsa05134 | Legionellosis | 4.75E-02 | 3 | P25963, P11215, P11142 | NFKBIA, ITGAM, HSPA8 | More | |
| Hydroxyzine | hsa05140 | Leishmaniasis | 4.82E-02 | 4 | P14598, P11215, P42224, P25963 | NCF1, ITGAM, STAT1, NFKBIA | More | |
| Hydroxyzine | hsa05143 | African trypanosomiasis | 2.72E-02 | 2 | P01375, P48023 | TNF, FASLG | More | |
| Hydroxyzine | hsa05144 | Malaria | 1.91E-02 | 3 | P01375, P35443, P26718 | TNF, THBS4, KLRK1 | More | |
| Hydroxyzine | hsa05146 | Amoebiasis | 2.41E-02 | 4 | P19875, P01375, P30679, P22694 | CXCL2, TNF, GNA15, PRKACB | More | |
| Hydroxyzine | hsa05152 | Tuberculosis | 3.98E-02 | 1 | P04049 | RAF1 | More | |
| Hydroxyzine | hsa05160 | Hepatitis C | 1.40E-03 | 5 | P60033, P04049, P49841, P01375, P48023 | CD81, RAF1, GSK3B, TNF, FASLG | More | |
| Hydroxyzine | hsa05161 | Hepatitis B | 1.99E-02 | 1 | P04049 | RAF1 | More | |
| Hydroxyzine | hsa05163 | Human cytomegalovirus infection | 3.15E-03 | 9 | P04049, P25963, P62873, P63218, P50151, P0DP23, Q14344, P30101, P01568 | RAF1, NFKBIA, GNB1, GNG5, GNG10, CALM1, GNA13, PDIA3, IFNA21 | More | |
| Hydroxyzine | hsa05164 | Influenza A | 3.65E-02 | 1 | P04049 | RAF1 | More | |
| Hydroxyzine | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 2.04E-05 | 11 | P01568, P42224, P25963, P62873, P63218, P50151, P19174, P04049, P07948, P04141, P0DP23 | IFNA21, STAT1, NFKBIA, GNB1, GNG5, GNG10, PLCG1, RAF1, LYN, CSF2, CALM1 | More | |
| Hydroxyzine | hsa05168 | Herpes simplex virus 1 infection | 3.79E-02 | 9 | P25963, P01568, P42224, Q07955, Q01130, Q13243, P30101, Q13398, O75820 | NFKBIA, IFNA21, STAT1, SFRS1, SFRS2, SFRS5, PDIA3, ZNF211, ZNF189 | More | |
| Hydroxyzine | hsa05170 | Human immunodeficiency virus 1 infection | 2.44E-03 | 9 | P04049, P62873, P63218, P50151, P0DP23, P30101, P01568, P25963, P19174 | RAF1, GNB1, GNG5, GNG10, CALM1, PDIA3, IFNA21, NFKBIA, PLCG1 | More | |
| Hydroxyzine | hsa05200 | Pathways in cancer | 1.99E-03 | 15 | P08238, P42224, P25963, P19174, P43246, P84022, P20585, P62873, P63218, P50151, Q14344, O75293, P0DP23, P01568, P14784 | HSP90AB1, STAT1, NFKBIA, PLCG1, MSH2, SMAD3, MSH3, GNB1, GNG5, GNG10, GNA13, GADD45B, CALM1, IFNA21, IL2RB | More | |
| Hydroxyzine | hsa05202 | Transcriptional misregulation in cancer | 8.55E-04 | 5 | P27930, P11215, P08069, Q13547, P12980 | IL1R2, ITGAM, IGF1R, HDAC1, LYL1 | More | |
| Hydroxyzine | hsa05203 | Viral carcinogenesis | 6.44E-03 | 4 | Q13547, P58876, Q16778, O60814 | HDAC1, H2BC5, HIST2H2BE, H2BC12 | More | |
| Hydroxyzine | hsa05205 | Proteoglycans in cancer | 2.86E-03 | 7 | P04049, P14780, P01375, P08069, P23588, Q13635, P22694 | RAF1, MMP9, TNF, IGF1R, EIF4B, PTCH1, PRKACB | More | |
| Hydroxyzine | hsa05206 | MicroRNAs in cancer | 3.15E-02 | 1 | P04049 | RAF1 | More | |
| Hydroxyzine | hsa05210 | Colorectal cancer | 1.66E-02 | 1 | P04049 | RAF1 | More | |
| Hydroxyzine | hsa05211 | Renal cell carcinoma | 1.16E-02 | 1 | P04049 | RAF1 | More | |
| Hydroxyzine | hsa05212 | Pancreatic cancer | 9.52E-03 | 4 | P04049, P42224, P84022, O75293 | RAF1, STAT1, SMAD3, GADD45B | More | |
| Hydroxyzine | hsa05213 | Endometrial cancer | 9.95E-03 | 1 | P04049 | RAF1 | More | |
| Hydroxyzine | hsa05214 | Glioma | 1.00E-03 | 5 | P08069, P0DP23, P04049, P19174, O75293 | IGF1R, CALM1, RAF1, PLCG1, GADD45B | More | |
| Hydroxyzine | hsa05215 | Prostate cancer | 1.65E-04 | 2 | P08069, P04049 | IGF1R, RAF1 | More | |
| Hydroxyzine | hsa05218 | Melanoma | 3.85E-05 | 2 | P08069, P04049 | IGF1R, RAF1 | More | |
| Hydroxyzine | hsa05219 | Bladder cancer | 4.98E-03 | 1 | P04049 | RAF1 | More | |
| Hydroxyzine | hsa05220 | Chronic myeloid leukemia | 9.95E-03 | 1 | P04049 | RAF1 | More | |
| Hydroxyzine | hsa05221 | Acute myeloid leukemia | 8.29E-03 | 1 | P04049 | RAF1 | More | |
| Hydroxyzine | hsa05223 | Non-small cell lung cancer | 6.63E-03 | 1 | P04049 | RAF1 | More | |
| Hydroxyzine | hsa05224 | Breast cancer | 2.11E-04 | 2 | P04049, P08069 | RAF1, IGF1R | More | |
| Hydroxyzine | hsa05225 | Hepatocellular carcinoma | 1.81E-05 | 4 | P04049, Q92529, P08069, P51531 | RAF1, SHC3, IGF1R, SMARCA2 | More | |
| Hydroxyzine | hsa05226 | Gastric cancer | 8.29E-03 | 1 | P04049 | RAF1 | More | |
| Hydroxyzine | hsa05230 | Central carbon metabolism in cancer | 9.95E-03 | 1 | P04049 | RAF1 | More | |
| Hydroxyzine | hsa05231 | Choline metabolism in cancer | 1.33E-02 | 1 | P04049 | RAF1 | More | |
| Hydroxyzine | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 1.66E-02 | 1 | P04049 | RAF1 | More | |
| Hydroxyzine | hsa05321 | Inflammatory bowel disease | 1.91E-02 | 3 | P01375, Q14765, Q9UL17 | TNF, STAT4, TBX21 | More | |
| Hydroxyzine | hsa05322 | Systemic lupus erythematosus | 1.18E-02 | 3 | P58876, Q16778, O60814 | H2BC5, HIST2H2BE, H2BC12 | More | |
| Hydroxyzine | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
| Hydroxyzine | hsa05332 | Graft-versus-host disease | 7.27E-04 | 4 | P48023, P01375, P26715, Q13241 | FASLG, TNF, KLRC1, KLRD1 | More | |
| Hydroxyzine | hsa05415 | Diabetic cardiomyopathy | 1.28E-02 | 4 | Q16718, O14521, Q16539, P49841 | NDUFA5, SDHD, MAPK14, GSK3B | More | |
